Annovis Bio, Inc.
NYSE:ANVS
Overview | Financials
Company Name | Annovis Bio, Inc. |
Symbol | ANVS |
Currency | USD |
Price | 4.37 |
Market Cap | 60,293,764 |
Dividend Yield | 0% |
52-week-range | 4.31 - 22.49 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Maria L. Maccecchini Ph.D. |
Website | https://www.annovisbio.com |
An error occurred while fetching data.
About Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD